Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Biogen
Study ID
NCT00090038
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — DRUG
    Dose, schedule,and duration specified in protocol

Study Details

The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.

Key Dates

Start date
Oct 31, 2003
Status verified
Oct 2009
Primary completion
Jun 30, 2007
Completion
Nov 30, 2007

Study Design

Enrollment
168 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Rituximab
  • No Intervention: 2
    No drug

Primary Outcome Measure

To determine whether treatment with rituximab causes a clinically significant effect on immunological recall response to tetanus vaccine in NHL patients [ Time Frame: 8.5 months after treatment ]

Locations (7)

FacilityCityStateZIPSite coordinators
USC KECK School of MedicineLos AngelesCalifornia90033-
Radiant ResearchHonoluluHawaii96814-
Carle Clinic AssociationUrbanaIllinois61801-
Tufts - New England Medical CenterBostonMassachusetts02111-
Our Lady of Mercy Medical CenterThe BronxNew York10466-
University of Pittsburth Cancer CentersPittsburghPennsylvania15232-
University of Texas Health Science Center at San AntonioSan AntonioTexas78229-3900-

Find similar trials in Los Angeles, CA

By research site
USC KECK School of Medicine· Los Angeles, CARadiant Research· Honolulu, HICarle Clinic Association· Urbana, ILTufts - New England Medical Center· Boston, MAOur Lady of Mercy Medical Center· The Bronx, NYUniversity of Pittsburth Cancer Centers· Pittsburgh, PA

Related Studies